Progression Free Survival Clinical Trial
Official title:
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib
Assess progression free survival, overall survival and toxicity of standard EP regimen combined or not with VEGF tyrosine kinase inhibitor-apatinib. Response measured by RECIST response criteria. Toxicity via physical exam, adverse event review, assessing signs and symptoms, quality of life assessment and blood testing. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01453257 -
Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients
|
Phase 2 | |
| Recruiting |
NCT03748680 -
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06338683 -
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
|
Phase 3 | |
| Completed |
NCT03769935 -
Maintenance Therapy for Small-cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05477797 -
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
|
N/A | |
| Completed |
NCT02959749 -
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
|
Phase 2/Phase 3 |